2024
Gene Copy Number Alterations Identify Subsets of Mycosis Fungoides/Sézary Syndrome Patients with Worse Survival Outcomes
Kiwan A, Kewan T, Xu M, Siddon A, Girardi M, Sethi T, Foss F. Gene Copy Number Alterations Identify Subsets of Mycosis Fungoides/Sézary Syndrome Patients with Worse Survival Outcomes. Blood 2024, 144: 4440-4440. DOI: 10.1182/blood-2024-205144.Peer-Reviewed Original ResearchGene copy number alterationsAssociated with poor OSAbsolute lymphocyte countFluorescence in situ hybridization panelAssociated with worse OSCirculating Tumor CellsFluorescence in situ hybridizationOverall survivalCopy number alterationsT cell receptorPoor OSSurvival outcomesTumor cellsMedian OSCox proportional hazardsBlood involvementATM deletionArid1a deletionT cellsElevated absolute lymphocyte countMedian absolute lymphocyte countAssociated with better OSMedian age of patientsMultivariate CPH modelZEB1 deletion
2022
Association of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma
Liu E, Vasudevaraja V, Sviderskiy V, Feng Y, Tran I, Serrano J, Cordova C, Kurz S, Golfinos J, Sulman E, Orringer D, Placantonakis D, Possemato R, Snuderl M. Association of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma. Neuro-Oncology Advances 2022, 4: vdac163. PMID: 36382106, PMCID: PMC9653172, DOI: 10.1093/noajnl/vdac163.Peer-Reviewed Original ResearchIDH-wt GBMAssociated with poor OSMethylation subclassesOverall survivalPoor OSIDH-wtMolecular subclassesRTK IAssociated with worse survivalAssociated with OSIDH-wildtype glioblastomaPotential survival benefitAssociation of hyperglycemiaAverage glucose valuesAverage glucoseStupp protocolDexamethasone doseMGMT statusSurvival benefitWorse survivalMesenchymal tumorsPerformance statusLow glucose levelsMGMT methylationMolecular subtypes
2021
NCOG-11. ASSOCIATION OF HYPERGLYCEMIA AND TUMOR SUBCLASS ON SURVIVAL IN IDH-WILDTYPE GLIOBLASTOMA
Liu E, Vasudevaraja V, Sviderskiy V, Feng Y, Tran I, Serrano J, Cordova C, Kurz S, Golfinos J, Sulman E, Placantonakis D, Possemato R, Snuderl M. NCOG-11. ASSOCIATION OF HYPERGLYCEMIA AND TUMOR SUBCLASS ON SURVIVAL IN IDH-WILDTYPE GLIOBLASTOMA. Neuro-Oncology 2021, 23: vi154-vi154. PMCID: PMC8598635, DOI: 10.1093/neuonc/noab196.602.Peer-Reviewed Original ResearchIDH-wt glioblastomaAssociated with poor OSMethylation subclassesDexamethasone doseOverall survivalPoor OSIDH-wtMolecular subclassesAssociated with worse survivalRNA expressionIDH-wildtype glioblastomaPotential survival benefitDNA methylation clustersIsocitrate dehydrogenase (IDH)-wildtypeAssociated with survivalClinical next-generation sequencingPlasma glucose measurementsDNA methylation studiesAverage glucoseNext-generation sequencingStupp protocolMGMT statusMesenchymal tumorsPrognostic significanceSurvival benefitFibrinogen/Albumin Ratio as a Promising Marker for Predicting Survival in Pancreatic Neuroendocrine Neoplasms
Deng S, Fan Z, Xia H, Gong Y, Qian Y, Huang Q, Cheng H, Jin K, Xiao Z, Luo G, Yu X, Liu C. Fibrinogen/Albumin Ratio as a Promising Marker for Predicting Survival in Pancreatic Neuroendocrine Neoplasms. Cancer Management And Research 2021, 13: 107-115. PMID: 33447083, PMCID: PMC7802789, DOI: 10.2147/cmar.s275173.Peer-Reviewed Original ResearchProgression-free survivalFibrinogen/albumin ratioIndependent risk factorOverall survivalPoor OSPan-NENsCutoff valuePrognostic valueMultivariate analysisAssociated with poor OSRisk factorsGrade 3 tumorsStage IV tumorsOptimal cutoff valuePancreatic neuroendocrine neoplasmsNonfunctioning tumorsIV tumorsNeuroendocrine neoplasmsPrimary endpointSecondary endpointsPredictive biomarkersClinicopathological characteristicsPredicting PrognosisUnivariate analysisPredicting Survival
2020
Venetoclax Therapy for Relapsed and Treatment Refractory AML: Clinical Outcomes and Molecular Predictors
Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, King A, Daniyan A, Famulare C, Cuello B, Abdel-Wahab O, Levine R, Viny A, Stein E, Roshal M, Tallman M, Goldberg A. Venetoclax Therapy for Relapsed and Treatment Refractory AML: Clinical Outcomes and Molecular Predictors. Blood 2020, 136: 47-48. DOI: 10.1182/blood-2020-137815.Peer-Reviewed Original ResearchCurrent equity holderEntity's Board of DirectorsRR-AMLRR-AML patientsMeasurable residual diseaseOverall survivalCombination therapyVenetoclax therapyAdverse cytogeneticsComplete responseResponse rateMedian OSRefractory AMLResidual diseaseEuropean LeukemiaNetMolecular predictorsClinical outcomesADC therapeuticsAssociated with prolonged OSCycle 1 day 1Venetoclax-based combination therapiesAllogeneic stem cell transplantationLevel of residual diseaseAssociated with poor OSMemorial Sloan Kettering Cancer Center
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply